Alluvi, previously BI 4744, represents a promising development in weight control therapy. This dual stimulator targeting both glucagon-like peptide-1 and GIP receptors demonstrates compelling effectiveness in clinical https://alluvi-healthcare026706.wikibriefing.com/user